Drug Type Antibody drug conjugate (ADC) |
Synonyms MM 015, MM-015 |
Target |
Mechanism CCR2 antagonists(C-C chemokine receptor type 2 antagonists), NAMPT inhibitors(Nicotinamide phosphoribosyltransferase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Myelomonocytic Leukemia | Preclinical | GB | 10 Dec 2023 |